Collegium Announces $25 Million Accelerated Share Repurchase Program
November 09, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium to Participate in Upcoming Investor Conferences
November 08, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Third Quarter 2023 Financial Results
November 07, 2023 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up...
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
August 28, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
August 24, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces $50 Million Accelerated Share Repurchase Program
August 07, 2023 07:30 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
August 03, 2023 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2’23 GAAP Net Income of $13.0 Million – – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has...
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
July 20, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium to Participate in Jefferies Healthcare Conference
June 01, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...